The estimated Net Worth of Ester Falconer is at least $27.9 Million dollars as of 1 September 2021. Dr Falconer owns over 875,000 units of AbCellera Biologics stock worth over $2,353,750 and over the last 4 years he sold ABCL stock worth over $25,500,000.
Dr has made over 3 trades of the AbCellera Biologics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 875,000 units of ABCL stock worth $14,778,750 on 1 September 2021.
The largest trade he's ever made was selling 1,000,000 units of AbCellera Biologics stock on 9 June 2021 worth over $25,500,000. On average, Dr trades about 718,750 units every 42 days since 2021. As of 1 September 2021 he still owns at least 875,000 units of AbCellera Biologics stock.
You can see the complete history of Dr Falconer stock trades at the bottom of the page.
Dr. Ester Falconer Ph.D. is the Chief Technology Officer at AbCellera Biologics.
Dr D is 46, he's been the Chief Technology Officer of AbCellera Biologics since . There are 4 older and 2 younger executives at AbCellera Biologics. The oldest executive at AbCellera Biologics Inc. is Tryn T. Stimart Esq., 51, who is the Chief Legal Officer & Corp. Sec..
Ester's mailing address filed with the SEC is C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER, A1, .
Over the last 4 years, insiders at AbCellera Biologics have traded over $394,042,033 worth of AbCellera Biologics stock and bought 6,630,906 units worth $88,015,834 . The most active insiders traders include Peter Thiel, Andrew Lo, and Holdings Ltd. Thermopylae. On average, AbCellera Biologics executives and independent directors trade stock every 23 days with the average trade being worth of $1,381,181. The most recent stock trade was executed by Holdings Ltd. Thermopylae on 29 August 2024, trading 283,516 units of ABCL stock currently worth $739,977.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics executives and other stock owners filed with the SEC include: